PL2303891T3 - Pirazolo-chinazoliny jako modulatory aktywności kinaz białkowych - Google Patents

Pirazolo-chinazoliny jako modulatory aktywności kinaz białkowych

Info

Publication number
PL2303891T3
PL2303891T3 PL09769164T PL09769164T PL2303891T3 PL 2303891 T3 PL2303891 T3 PL 2303891T3 PL 09769164 T PL09769164 T PL 09769164T PL 09769164 T PL09769164 T PL 09769164T PL 2303891 T3 PL2303891 T3 PL 2303891T3
Authority
PL
Poland
Prior art keywords
quinazolines
pyrazolo
protein kinase
kinase activity
activity modulators
Prior art date
Application number
PL09769164T
Other languages
English (en)
Inventor
Marina Caldarelli
Mauro Angiolini
Riccardo Colombo
Teresa Disingrini
Stefano Nuvoloni
Helena Posteri
Matteo Salsa
Marco Silvagni
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40887152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2303891(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of PL2303891T3 publication Critical patent/PL2303891T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL09769164T 2008-06-26 2009-06-17 Pirazolo-chinazoliny jako modulatory aktywności kinaz białkowych PL2303891T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08159114 2008-06-26
EP09769164.6A EP2303891B1 (en) 2008-06-26 2009-06-17 Pyrazolo-quinazolines as protein kinase activity modulators
PCT/EP2009/057512 WO2009156315A1 (en) 2008-06-26 2009-06-17 Pyrazolo-quinazolines

Publications (1)

Publication Number Publication Date
PL2303891T3 true PL2303891T3 (pl) 2016-08-31

Family

ID=40887152

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09769164T PL2303891T3 (pl) 2008-06-26 2009-06-17 Pirazolo-chinazoliny jako modulatory aktywności kinaz białkowych

Country Status (21)

Country Link
US (1) US8846701B2 (pl)
EP (1) EP2303891B1 (pl)
JP (1) JP5542133B2 (pl)
CN (1) CN102076689B (pl)
AR (2) AR072374A1 (pl)
AU (1) AU2009264431B2 (pl)
BR (1) BRPI0914649B1 (pl)
CA (1) CA2729436C (pl)
CL (1) CL2010001538A1 (pl)
CY (1) CY1117595T1 (pl)
DK (1) DK2303891T3 (pl)
EA (1) EA020703B9 (pl)
ES (1) ES2572360T3 (pl)
HK (1) HK1154383A1 (pl)
HR (1) HRP20160243T1 (pl)
HU (1) HUE027527T2 (pl)
MX (1) MX2010013843A (pl)
PL (1) PL2303891T3 (pl)
SI (1) SI2303891T1 (pl)
TW (1) TWI464172B (pl)
WO (1) WO2009156315A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009071480A2 (en) * 2007-12-04 2009-06-11 Nerviano Medical Sciences S.R.L. Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
JP5662411B2 (ja) * 2009-03-27 2015-01-28 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｍｐｓ１キナーゼ阻害剤としてのｎ−アリール−２−（２−アリールアミノピリミジン−４−イル）ピロール−４−カルボキサミド誘導体
EP2598508B1 (en) 2010-07-30 2015-04-22 Nerviano Medical Sciences S.r.l. Isoxazolo-quinazolines as modulators of protein kinase activity
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
WO2012080232A1 (en) * 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
BR112013008527A2 (pt) 2010-12-17 2016-07-12 Nerviano Medical Sciences Srl derivados de pirazolo-quinazolina substituídos como inibidores de cinase
WO2012098207A1 (en) * 2011-01-21 2012-07-26 Basilea Pharmaceutica Ag Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles
US8916577B2 (en) 2011-01-26 2014-12-23 Nerviano Medical Sciences S.R.L. Tricyclic derivatives, process for their preparation and their use as kinase inhibitors
RU2591191C2 (ru) 2011-01-26 2016-07-10 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Трициклические пирроло производные, способ их получения и их применение в качестве ингибиторов киназы
JP5976778B2 (ja) * 2011-04-11 2016-08-24 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤としてのピラゾリル−ピリミジン誘導体
EP2836482B1 (en) * 2012-04-10 2019-12-25 The Regents of The University of California Compositions and methods for treating cancer
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
CN103130810B (zh) * 2013-03-11 2015-02-25 河南师范大学 一种吡唑并[1,5-c]喹唑啉类化合物的合成方法
WO2015155042A1 (en) * 2014-04-07 2015-10-15 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines
EP3283642B1 (en) 2015-04-17 2023-10-11 Netherlands Translational Research Center Holding B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
UY37778A (es) * 2017-06-29 2019-01-31 Servier Lab NUEVA SAL DE N-(2,6-DIETILFENIL)-8-({4-[4-(DIMETILAMINO)PIPERIDIN-1-IL]-2- METOXIFENIL}AMINO)-1-METIL-4,5-DIHIDRO- 1H-PIRAZOLO[4,3-h]QUINAZOLINA-3- CARBOXAMIDA, SU PREPARACIÓN, Y LAS FORMULACIONES QUE LA CONTIENEN
AR112217A1 (es) 2017-06-30 2019-10-02 Servier Lab Una combinación de un inhibidor de mps1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
JP7178401B2 (ja) * 2017-07-11 2022-11-25 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ コリンキナーゼ阻害剤としてのピラゾロキナゾリン誘導体
ES2923415T3 (es) 2017-08-11 2022-09-27 Shengke Pharmaceuticals Jiangsu Ltd Compuesto de 1H-pirazolo[4,3-H]quinazolina que sirve como inhibidor de proteína quinasa
WO2021195360A1 (en) * 2020-03-27 2021-09-30 Landos Biopharma, Inc. Plxdc2 ligands
US20230416271A1 (en) * 2020-11-26 2023-12-28 Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. Heteroarylquinazoline compounds as protein kinase inhibitors
CN114685520A (zh) * 2020-12-25 2022-07-01 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
WO2022143576A1 (zh) * 2020-12-31 2022-07-07 恒元生物医药科技(苏州)有限公司 一种吡唑并喹唑啉类化合物、其制备方法及应用
WO2023113478A1 (en) * 2021-12-15 2023-06-22 Sillajen, Inc. Methods of treating neoplastic diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057329A (en) * 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
JP2005526730A (ja) * 2002-02-19 2005-09-08 ファルマシア・コーポレーション 炎症の治療のための三環系ピラゾール誘導体
CA2526578C (en) * 2003-05-22 2012-01-24 Pharmacia Italia S.P.A. Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
KR101512284B1 (ko) * 2006-12-21 2015-04-15 네르비아노 메디칼 사이언시스 에스.알.엘. 치환된 피라졸로-퀴나졸린 유도체, 이의 제조방법, 및 키나제 억제제로서의 이의 용도

Also Published As

Publication number Publication date
DK2303891T3 (en) 2016-05-30
CL2010001538A1 (es) 2012-02-03
AU2009264431A2 (en) 2011-02-17
TWI464172B (zh) 2014-12-11
JP2011525516A (ja) 2011-09-22
US8846701B2 (en) 2014-09-30
AR072374A1 (es) 2010-08-25
EP2303891A1 (en) 2011-04-06
BRPI0914649A2 (pt) 2015-07-07
CA2729436A1 (en) 2009-12-30
ES2572360T3 (es) 2016-05-31
US20110105542A1 (en) 2011-05-05
TW201004960A (en) 2010-02-01
SI2303891T1 (sl) 2016-06-30
EA020703B9 (ru) 2015-12-30
EP2303891B1 (en) 2016-02-17
HUE027527T2 (en) 2016-10-28
HRP20160243T1 (hr) 2016-04-08
JP5542133B2 (ja) 2014-07-09
WO2009156315A1 (en) 2009-12-30
EA020703B1 (ru) 2015-01-30
CN102076689B (zh) 2014-10-15
BRPI0914649B1 (pt) 2021-07-06
CA2729436C (en) 2016-08-09
MX2010013843A (es) 2011-01-21
CY1117595T1 (el) 2017-04-26
CN102076689A (zh) 2011-05-25
AU2009264431B2 (en) 2013-11-07
HK1154383A1 (en) 2012-04-20
AR113818A2 (es) 2020-06-17
EA201170090A1 (ru) 2011-08-30
AU2009264431A1 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
SI2303891T1 (sl) Pirazolo kinazolini kot modulatorji aktivnosti protein kinaze
HUS1900014I1 (hu) Proteinkináz inhibitorok
EP2259678A4 (en) PROTEIN KINASE MODULATORS
ZA201005245B (en) Protein expression systems
ZA201203849B (en) Novel kinase modulators
ZA201006033B (en) Microencapsulation
ZA201201627B (en) Compounds as tyrosine kinase modulators
HRP20170959T1 (hr) Farmaceutska suspenzija
EP2306836A4 (en) MODULATORS OF BMI-1 PROTEIN EXPRESSION
PL2145914T3 (pl) Preparaty plastyfikatorów
IL210073A0 (en) Protein kinase inhibitors
PL2329032T3 (pl) Sposoby wykorzystujące polipeptydy o aktywności hydrolazy
GB0823326D0 (en) Self-calibration
IL210069A0 (en) Protein kinase inhibitors
PL2625176T3 (pl) Podstawione związki 6-amino-pirydazyn-3-ylo-karboksyamidu jako modulatory kinazy białkowej
GB2462761B (en) Protein formulation
GB2466379B (en) Protein stabilizer
GB0816976D0 (en) Protein
GB0817507D0 (en) Protein cages
TWI373184B (en) Control center
GB0813253D0 (en) Protein expression system
GB2462726B (en) Protein expression
GB0818627D0 (en) Protein
GB0810567D0 (en) Protein expression
GB0811893D0 (en) Protein expression